Patents by Inventor Nigel Alan Swain

Nigel Alan Swain has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • CGRP ANTAGONIST COMPOUNDS
    Publication number: 20250136616
    Abstract: The disclosures herein relate to novel compounds of Formula (1a): and salts thereof, wherein W, Z, L, R1 and R2 are defined herein, and their use in treating, preventing, ameliorating, controlling or reducing the risk of disorders associated with CGRP receptors.
    Type: Application
    Filed: December 31, 2024
    Publication date: May 1, 2025
    Inventors: Giles Albert Brown, Miles Stuart Congreve, Stephen Paul Watson, Julie Cansfield, Michael Alistair O'Brien, Francesca Deflorian, Gregory R. Ott, Nigel Alan Swain, Andrew David Cansfield
  • PYRAZOLE DERIVATIVES AS H4 ANTAGONIST COMPOUNDS
    Publication number: 20250115587
    Abstract: The disclosures herein relate to novel compounds of formula (1): and salts thereof, wherein A; X; n; R1 and R2 are defined herein, and their use in treating, preventing, ameliorating, controlling or reducing the risk of disorders associated with H4 receptors.
    Type: Application
    Filed: September 5, 2024
    Publication date: April 10, 2025
    Inventors: Giles Albert Brown, Miles Stuart Congreve, Barry John Teobald, Charlotte Fieldhouse, Nigel Alan Swain, Mark Pickworth, Giovanni Bottegoni
  • Oxexin 1 receptor antagonists
    Patent number: 12240825
    Abstract: The disclosures herein relate to novel compounds of formula (1) and salts thereof, wherein V; W; X; Y; Z; R1; R2; R3; R4 and R5 are defined herein, and their use in treating, preventing, ameliorating, controlling or reducing the risk of neurological or psychiatric disorders associated with orexin receptors.
    Type: Grant
    Filed: January 28, 2020
    Date of Patent: March 4, 2025
    Assignee: NXERA PHARMA UK LIMITED
    Inventors: Giles Albert Brown, Miles Stuart Congreve, John Andrew Christopher, Nigel Alan Swain, Sarah Joanne Bucknell, Anne Mary Stephenson, Benjamin Gerald Tehan, Geraint Jones, Mark Mills, Anil Patel, Andrew William Phillips
  • Pyrazole derivatives as H4 antagonist compounds
    Patent number: 12234227
    Abstract: Novel compounds of formula (1): and salts thereof, wherein A; X; n; R1 and R2 are defined herein, are disclosed, as well as their use in treating, preventing, ameliorating, controlling or reducing the risk of disorders associated with H4 receptors.
    Type: Grant
    Filed: October 21, 2019
    Date of Patent: February 25, 2025
    Assignee: NXERA PHARMA UK LIMITED
    Inventors: Giles Albert Brown, Miles Stuart Congreve, Barry John Teobald, Charlotte Fieldhouse, Nigel Alan Swain, Mark Pickworth, Giovanni Bottegoni
  • CGRP antagonist compounds
    Patent number: 12227521
    Abstract: The disclosures herein relate to novel compounds of Formula (1a): and salts thereof, wherein W, Z, L, R1 and R2 are defined herein, and their use in treating, preventing, ameliorating, controlling or reducing the risk of disorders associated with CGRP receptors.
    Type: Grant
    Filed: June 12, 2020
    Date of Patent: February 18, 2025
    Assignee: Nxera Pharma UK Limited
    Inventors: Giles Albert Brown, Miles Stuart Congreve, Stephen Paul Watson, Julie Cansfield, Michael Alistair O'Brien, Francesca Deflorian, Gregory R. Ott, Nigel Alan Swain, Andrew David Cansfield
  • GPR52 MODULATOR COMPOUNDS
    Publication number: 20240376070
    Abstract: The disclosures herein relate to novel compounds of Formula (1a) or (1b) or a salt thereof, wherein R1, R2, R3, R4, R8, R9 and R10 are defined herein, and their use in treating, preventing, ameliorating, controlling or reducing the risk of disorders associated with GPR52 receptors.
    Type: Application
    Filed: September 15, 2022
    Publication date: November 14, 2024
    Applicant: NXERA PHARMA UK LIMITED
    Inventors: Stephen Paul WATSON, Nigel Alan SWAIN, Michael Alistair O'BRIEN
  • H4 Antagonist Compounds
    Publication number: 20240317775
    Abstract: The disclosures herein relate to novel compounds of formula (1): and salts thereof, wherein Y, Z, R1, R2, R3, R4, R5 and n are defined herein, and their use in treating, preventing, ameliorating, controlling or reducing the risk of disorders associated with H4 receptors.
    Type: Application
    Filed: December 14, 2021
    Publication date: September 26, 2024
    Inventors: Giles Albert BROWN, Miles Sturt CONGREVE, Barry TEOBALD, Nigel Alan SWAIN, Charlootte FIELDHOUSE, Mark PICKWORTH, Malken BAYRAKDARIAN, Delphine KARILA, Danail BEAUDION
  • GPR35 Agonist Compounds
    Publication number: 20240254093
    Abstract: The disclosures herein relate to novel compounds of formula (1): and salts and any tautomers thereof, wherein X, R1 and R2 are defined herein, and their use in treating, preventing, ameliorating, controlling or reducing the risk of disorders associated with GPR35 receptors.
    Type: Application
    Filed: April 22, 2022
    Publication date: August 1, 2024
    Inventors: Miles Stuart CONGREVE, Nigel Alan SWAIN, Giles Albert BROWN, Benjamin WHITEHURST, Neil John FLANGAN
  • H4 ANTAGONIST COMPOUNDS
    Publication number: 20230167094
    Abstract: The disclosure herein relates to azetidinylpyrimidin-2-amine derivatives, their use as Histamine H4 receptor antagonists and their use in treating, preventing, ameliorating, controlling or reducing the risk of disorders associated with H4 receptors.
    Type: Application
    Filed: April 22, 2021
    Publication date: June 1, 2023
    Applicant: Heptares Therapeutics Limited
    Inventors: Miles Stuart CONGREVE, Charlotte FIELDHOUSE, Nigel Alan SWAIN, Mark PICKWORTH, Duncan Robert HANNAH
  • 5-AMINO-8-(4-PYRIDYL)-[1,2,4]TRIAZOLO[4,3-C]PYRIMIDIN-3-ONE COMPOUNDS FOR USE AGAINST CANCER
    Publication number: 20230146483
    Abstract: Described herein are triazalone compounds of Formula (I): and pharmaceutically acceptable salts thereof. Methods of making and using compounds of Formula (I) are also described. Compounds of Formula (I) and pharmaceutically acceptable salts thereof can be useful as adenosine receptor antagonists, for example in the treatment of diseases or conditions mediated by the adenosine receptor, such as cancer, movement disorders, or attention disorders.
    Type: Application
    Filed: March 25, 2021
    Publication date: May 11, 2023
    Inventors: Giles Albert Brown, Miles Stuart Congreve, Christine Mary Richardson, Rebecca Paul, Stephen Philippe Andrews, Jonathan Stephen Mason, Francesca Deflorian, Nigel Alan Swain
  • TRIAZOLONE COMPOUNDS
    Publication number: 20230146796
    Abstract: Described herein are triazalone compounds of Formula (I): and pharmaceutically acceptable salts thereof. Methods of making and using compounds of Formula (I) are also described. Compounds of Formula (I) and pharmaceutically acceptable salts thereof can be useful as adenosine receptor antagonists, for example in the treatment of diseases or conditions mediated by the adenosine receptor, such as cancer, movement disorders, or attention disorders.
    Type: Application
    Filed: March 25, 2021
    Publication date: May 11, 2023
    Applicant: ASTRAZENECA AB
    Inventors: Giles Albert Brown, Miles Stuart Congreve, Stephen Philippe Andrews, Jonathan Stephen Mason, Francesca Deflorian, Nigel Alan Swain
  • GPR52 MODULATOR COMPOUNDS
    Publication number: 20230002374
    Abstract: The disclosures herein relate to novel compounds of Formula (1): (1) and salts thereof, wherein R1, Q, X, Y and Z are defined herein, and their use in treating, preventing, ameliorating, controlling or reducing the risk of disorders associated with GPR52 receptors.
    Type: Application
    Filed: November 9, 2020
    Publication date: January 5, 2023
    Inventors: Sarah Joanne Bucknell, Stephen Paul Watson, Michael Alistair O'Brien, Chris De Graaf, Nigel Alan Swain
  • PROSTAGLANDIN EP4 RECEPTOR ANTAGONIST COMPOUNDS
    Publication number: 20220411364
    Abstract: The disclosures herein relate to novel compounds of formula (1): (1) and salts thereof, wherein A, X, R1, R2, R3, R4, R10 and R11 are defined herein, and their use in treating, preventing, ameliorating, controlling or reducing the risk of disorders associated with EP4 receptors.
    Type: Application
    Filed: October 9, 2020
    Publication date: December 29, 2022
    Inventors: Miles Stuart Congreve, Nigel Alan Swain, Benjamin Whitehurst
  • CGRP ANTAGONIST COMPOUNDS
    Publication number: 20220306651
    Abstract: The disclosures herein relate to novel compounds of Formula (1): and salts thereof, wherein A1, A2, Q, X, R1, R2 and R3 are defined herein, and their use in treating, preventing, ameliorating, controlling or reducing the risk of disorders associated with CGRP receptors.
    Type: Application
    Filed: June 12, 2020
    Publication date: September 29, 2022
    Inventors: Giles Albert Brown, Miles Stuart Congreve, Stephen Paul Watson, Julie Cansfield, Michael Alistair O'Brien, Francesca Deflorian, Gregory R. Ott, Nigel Alan Swain, Andrew David Cansfield, John Andrew Christopher, Andrea Bortolato
  • CGRP ANTAGONIST COMPOUNDS
    Publication number: 20220251110
    Abstract: The disclosures herein relate to novel compounds of Formula (1a): and salts thereof, wherein W, Z, L, R1 and R2 are defined herein, and their use in treating, preventing, ameliorating, controlling or reducing the risk of disorders associated with CGRP receptors.
    Type: Application
    Filed: June 12, 2020
    Publication date: August 11, 2022
    Inventors: Giles Albert Brown, Miles Stuart Congreve, Stephen Paul Watson, Julie Cansfield, Michael Alistair O'Brien, Francesca Deflorian, Gregory R. Ott, Nigel Alan Swain, Andrew David Cansfield
  • OXEXIN 1 RECEPTOR ANTAGONISTS
    Publication number: 20220098165
    Abstract: The disclosures herein relate to novel compounds of formula (1) and salts thereof, wherein V; W; X; Y; Z; R1; R2; R3; R4 and R5 are defined herein, and their use in treating, preventing, ameliorating, controlling or reducing the risk of neurological or psychiatric disorders associated with orexin receptors.
    Type: Application
    Filed: January 28, 2020
    Publication date: March 31, 2022
    Inventors: Giles Albert Brown, Miles Stuart Congreve, John Andrew Christopher, Nigel Alan Swain, Sarah Joanne Bucknell, Anne Mary Stephenson, Benjamin Gerald Tehan, Geraint Jones, Mark Mills, Anil Patel, Andrew William Phillips
  • OREXIN 1 RECEPTOR ANTAGONISTS
    Publication number: 20220041573
    Abstract: The disclosures herein relate to novel compounds of formula (I): and salts thereof, wherein W; X; Y; Z; R1; R2; R3 and R4 are defined herein, and their use in treating, preventing, ameliorating, controlling or reducing the risk of neurological or psychiatric disorders associated with orexin receptors.
    Type: Application
    Filed: December 16, 2019
    Publication date: February 10, 2022
    Applicants: Heptares Therapeutics Limited, Heptares Therapeutics Limited
    Inventors: Giles Albert Brown, Miles Stuart Congreve, John Andrew Christopher, Nigel Alan Swain, Sarah Joanne Bucknell, Anne Mary Stephenson, Benjamin Gerald Tehan, Mark Mills, Anil Patel
  • PYRAZOLE DERIVATIVES AS H4 ANTAGONIST COMPOUNDS
    Publication number: 20210300906
    Abstract: The disclosures herein relate to novel compounds of formula (1): and salts thereof, wherein A; X; n; R1 and R2 are defined herein, and their use in treating, preventing, ameliorating, controlling or reducing the risk of disorders associated with H4 receptors.
    Type: Application
    Filed: October 21, 2019
    Publication date: September 30, 2021
    Inventors: Giles Albert Brown, Miles Stuart Congreve, Barry John Teobald, Charlotte Fieldhouse, Nigel Alan Swain, Mark Pickworth, Giovanni Bottegoni
  • OX1 ANTAGONISTS
    Publication number: 20210179578
    Abstract: The disclosures herein relate to novel compounds of formula (1) and salts thereof, wherein X; Y; R1; R2; R3; R4; R5; R6; R7 and R8 are defined herein, and their use in treating, preventing, ameliorating, controlling or reducing the risk of neurological or psychiatric disorders associated with orexin receptors.
    Type: Application
    Filed: November 5, 2018
    Publication date: June 17, 2021
    Inventors: John Andrew Christopher, Sarah Joanne Bucknell, Miles Stuart Congreve, Benjamin Gerald Tehan, Rebecca Helen Nonoo, Giles Albert Brown, Nigel Alan Swain, Mark Mills
  • N-ACYLPIPERIDINE ETHER TROPOMYOSIN-RELATED KINASE INHIBITORS
    Publication number: 20170305857
    Abstract: The present invention relates to compounds of Formula (I) described herein and their pharmaceutically acceptable salts, and their use in medicine, in particular as Trk antagonists.
    Type: Application
    Filed: December 8, 2014
    Publication date: October 26, 2017
    Applicant: Pfizer Limited
    Inventors: SARAH ELIZABETH SKERRATT, SHARANJEET KAUR BAGAL, NIGEL ALAN SWAIN, KIYOYUKI OMOTO, MARK DAVID ANDREWS